Raanana, Israel

Yasmin Maor

This inventor holds 1 USPTO granted patent. Top assignee: Yeda Research and Develpment & Co. Ltd. Active years: 1995.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 1995

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yasmin Maor: Innovator in Cancer Treatment

Introduction

Yasmin Maor is a prominent inventor based in Raanana, Israel. She has made significant contributions to the field of cancer treatment, particularly in the area of chronic lymphocytic leukemia (CLL). Her innovative work has led to the development of a patent that addresses critical therapeutic needs in oncology.

Latest Patents

Yasmin Maor holds a patent for the "Use of IL-6 for the treatment of chronic lymphocyte leukemia (CLL)." This patent encompasses the use of interleukin-6 and its derivatives in treating CLL and B-cell lymphomas. The patent also includes methods for combining these treatments with soluble interleukin-6 receptors, providing a comprehensive approach to managing these conditions.

Career Highlights

Yasmin is associated with Yeda Research and Development Co. Ltd., where she has been instrumental in advancing research and development in her field. Her work has not only contributed to scientific knowledge but has also paved the way for potential new therapies for patients suffering from CLL and related disorders.

Collaborations

Throughout her career, Yasmin has collaborated with esteemed colleagues, including Dan Aderka and David Wallach. These partnerships have enhanced her research efforts and have been vital in the progression of her innovative projects.

Conclusion

Yasmin Maor's contributions to cancer treatment through her patent and research exemplify her dedication to improving patient outcomes. Her work continues to inspire advancements in the medical field, particularly in the treatment of chronic lymphocytic leukemia.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…